Erratum to: Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study

  • Noriko Ujihara
  • Hiroshi Sakura
  • Naotake Hashimoto
  • Kazuo Sasamoto
  • Hiroshi Ohashi
  • Sumiko Hasumi
  • Tadasu Kasahara
  • Osamu Tomonaga
  • Hideo Nunome
  • Masashi Honda
  • Yasuhiko Iwamoto
  • for the JAMP Study Investigators
Erratum
  • 98 Downloads

Erratum to: Diabetol Int DOI 10.1007/s13340-017-0330-2

In the original publication of the article, a percentage symbol has been included incorrectly in the value of Alcohol consumption (65–74 years) as 45.1% in Table 1. The correct version is published with this erratum.
Table 1

Comparison of patient characteristics between the elderly and non-elderly patients

 

≥ 75 years (n = 130)

65–74 years (n = 189)

< 65 years (n = 332)

p

n

Mean ± SD or %

n

Mean ± SD or %

n

Mean ± SD or %

Age (years)

130

80.0 ± 4.7

189

69.2 ± 2.9

332

54.5 ± 7.4

0.000*

Height (cm)

127

156.2 ± 9.6

187

161.0 ± 8.6

328

166.2 ± 8.8

0.000*

Waist circumference (cm)

80

85.7 ± 10.5

120

87.3 ± 9.6

193

89.9 ± 12.0

0.009*

Duration of diabetes (days)

111

121.4 ± 94.6

181

114.1 ± 78.4

308

95.4 ± 74.4

0.003*

Sex (male)

67

51.5

117

61.9

250

75.3

0.000*

Smoking

13

10.3

34

18.6

96

29.8

0.000*

Alcohol consumption

39

31.7

82

45.1

180

56.1

0.000*

Retinopathy

8

6.2

8

4.2

32

9.6

0.064

Arteriosclerosis obliterans

6

4.6

21

11.1

28

8.4

0.122

Stroke

0

0.0

1

0.6

0

0.0

0.288

Myocardial infarction

7

5.4

5

2.6

6

1.8

0.108

Angina pectoris

8

6.2

8

4.2

11

3.3

0.387

Cardiac failure

5

3.8

2

1.1

4

1.2

0.102

Atrial fibrillation

4

3.1

5

2.6

7

2.1

0.817

Diet/exercise therapy

49

37.7

48

25.4

92

27.7

0.044*

Low dose of glimepiride

18

13.8

25

13.2

29

8.7

0.153

Medium dose of glimepiride

9

6.9

21

11.1

20

6.0

0.104

BG

9

6.9

25

13.2

65

19.6

0.002*

TZD

7

5.4

12

6.3

19

5.7

0.929

α-GI

5

3.8

3

1.6

10

3.0

0.446

Multidrug therapy

33

25.4

55

29.1

97

29.2

0.692

Antihypertensive drug

81

62.3

106

56.1

144

43.4

0.000*

Antihyperlipidemic drug

62

47.7

94

49.7

156

47.0

0.832

Antihyperuricemic drug

6

4.6

9

4.8

16

4.8

0.996

Antithrombogenic drug

22

16.9

44

23.3

52

15.7

0.088

p < 0.05

Copyright information

© The Japan Diabetes Society 2017

Authors and Affiliations

  • Noriko Ujihara
    • 1
  • Hiroshi Sakura
    • 2
  • Naotake Hashimoto
    • 3
  • Kazuo Sasamoto
    • 4
  • Hiroshi Ohashi
    • 5
  • Sumiko Hasumi
    • 6
  • Tadasu Kasahara
    • 7
  • Osamu Tomonaga
    • 8
  • Hideo Nunome
    • 9
  • Masashi Honda
    • 10
  • Yasuhiko Iwamoto
    • 11
  • for the JAMP Study Investigators
  1. 1.Department of Medicine, Diabetes Center, Institute of GeriatricsTokyo Women’s Medical UniversityTokyoJapan
  2. 2.Department of MedicineTokyo Women’s Medical University, Medical Center EastTokyoJapan
  3. 3.Department of Diabetes, Endocrine and Metabolic DiseasesTokyo Women’s Medical University Yachiyo Medical CenterYachiyo-shiJapan
  4. 4.Internal MedicineSuzuki ClinicTokyoJapan
  5. 5.Internal MedicineOyama East ClinicOyama-shiJapan
  6. 6.Internal MedicineNishiyamado-Keiwa HospitalNaka-shiJapan
  7. 7.Josai HospitalTokyoJapan
  8. 8.Diabetes and Lifestyle CenterTomonaga ClinicTokyoJapan
  9. 9.Diabetes Center, Edogawa Hospital, Medical Plaza ShinozakiTokyoJapan
  10. 10.Nishikawa ClinicTokyoJapan
  11. 11.Tokyo Women’s Medical University/The Institute for Adult Diseases, Asahi Life FoundationTokyoJapan

Personalised recommendations